Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × talazoparib × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroectodermal Tumors, Primitive, Peripheral 2 Wilms Tumor 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Pheochromocytoma 1 Paraganglioma 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Hepatoblastoma 1 Glioma 1 Glioblastoma 1 Central Nervous System Neoplasms 1

Interventions

Temozolomide 143 Bevacizumab 63 Radiotherapy 60 Magnetic Resonance Spectroscopy 58 Irinotecan 27 Carboplatin 23 Surgical Procedures, Operative 22 Radiation 19 Carmustine 18 Aminolevulinic Acid 18 Specimen Handling 17 Nivolumab 16 Blood Specimen Collection 16 Lomustine 15 Biopsy 15 pembrolizumab 13 Radiotherapy, Intensity-Modulated 12 Cyclophosphamide 12 trametinib 11 Topotecan 11 Radiosurgery 11 Erlotinib Hydrochloride 11 fluorodopa F 18 10 X-Rays 10 IL13-PE38 9 Everolimus 9 ribociclib 8 dabrafenib 8 Surveys and Questionnaires 8 Magnetic Resonance Imaging 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04740190 2025-06-11

TAC-GReD

The University of Hong Kong

Phase 2 Completed

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡